Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome

Journal of Pathology - Tập 202 Số 2 - Trang 145-156 - 2004
Madhav Bhatia1, Shabbir Moochhala2
1Department of Pharmacology, National University of Singapore, Singapore
2Combat Care and Performance Laboratory, Defence Medical Research Institute, Singapore

Tóm tắt

Abstract

Inflammatory response leading to organ dysfunction and failure continues to be the major problem after injury in many clinical conditions such as sepsis, severe burns, acute pancreatitis, haemorrhagic shock, and trauma. In general terms, systemic inflammatory response syndrome (SIRS) is an entirely normal response to injury. Systemic leukocyte activation, however, is a direct consequence of a SIRS and if excessive, can lead to distant organ damage and multiple organ dysfunction syndrome (MODS). When SIRS leads to MODS and organ failure, the mortality becomes high and can be more than 50%. Acute lung injury that clinically manifests as acute respiratory distress syndrome (ARDS) is a major component of MODS of various aetiologies. Inflammatory mediators play a key role in the pathogenesis of ARDS, which is the primary cause of death in these conditions. This review summarizes recent studies that demonstrate the critical role played by inflammatory mediators such as tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β, IL‐6, platelet activating factor (PAF), IL‐10, granulocyte macrophage‐colony stimulating factor (GM‐CSF), C5a, intercellular adhesion molecule (ICAM)‐1, substance P, chemokines, VEGF, IGF‐I, KGF, reactive oxygen species (ROS), and reactive nitrogen species (RNS) in the pathogenesis of ARDS. It is reasonable to speculate that elucidation of the key mediators in ARDS coupled with the discovery of specific inhibitors would make it possible to develop clinically effective anti‐inflammatory therapy. Copyright © 2004 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1038/nature01326

10.1097/00003246-200107001-00035

10.1007/s001340051121

10.1016/S0140-6736(67)90168-7

10.1164/ajrccm.149.3.7509706

10.1146/annurev.med.52.1.221

10.1006/pupt.2001.0325

10.1002/(SICI)1096-9896(200002)190:2<117::AID-PATH494>3.0.CO;2-K

Bhatia M, 2001, Inflammatory mediators as therapeutic targets in acute pancreatitis, Curr Opin Invest Drugs, 2, 496

10.2174/1568010023344517

10.1016/S0039-6109(16)46587-4

10.1001/archsurg.1995.01430090052018

10.1007/s001340000647

10.1172/JCI113431

10.1164/ajrccm.164.10.2104013

10.3109/01902148909069633

10.1378/chest.108.5.1303

10.1164/ajrccm.154.3.8810593

10.1164/ajrccm.150.1.8025734

10.1165/ajrcmb.10.6.8003342

10.1097/00003246-199707000-00010

10.1097/00003246-200103000-00006

Nijsten NWN, 1991, Interleukin‐6 and its relation to the humoral immune response and clinical response in burnt patients, Surgery, 109, 761

10.1097/00003246-199603000-00006

10.1002/eji.1830180510

10.1016/0014-5793(89)80476-4

10.1016/0016-5085(91)90539-W

10.1097/00024382-200206000-00004

10.4049/jimmunol.152.7.3559

10.4049/jimmunol.147.11.3815

10.1007/BF00918147

10.1084/jem.177.4.1205

10.1002/jlb.55.6.711

10.4049/jimmunol.158.4.1971

10.1002/eji.1830250443

10.1006/jsre.1998.5418

10.1136/thx.52.5.442

10.1016/S0305-4179(02)00113-4

10.1016/S0039-6060(96)80299-6

10.1007/s101560050050

10.1097/00002281-200211000-00009

10.1038/359693a0

10.1136/thx.48.10.959

10.1073/pnas.88.15.6642

10.1172/JCI11963

10.1165/ajrcmb.11.3.8086171

10.1146/annurev.physiol.64.090601.113847

10.1086/513802

10.1007/s00134-002-1335-1

10.1164/rccm.2009005

Prescott SM, 1999, Inflammation: Basic Principles and Clinical Correlates, 387

10.1172/JCI7727

10.1002/bjs.1800811224

10.1016/S0016-5085(98)70096-4

10.1385/IJGC:23:2:101

10.1084/jem.187.11.1779

10.1136/gut.48.1.62

10.1097/00024382-200014040-00001

10.1128/AAC.44.3.693-696.2000

10.1093/bja/77.1.17

10.1002/jlb.66.6.876

10.1046/j.1365-2168.1998.00770.x

10.1164/rccm.2108122

10.1002/path.1186

10.1164/ajrccm.161.5.9907104

10.1007/BF02788564

10.1016/S0016-5085(99)70192-7

10.1146/annurev.iy.12.040194.004015

10.1002/jlb.64.1.40

10.1038/nm0895-839

10.1038/383086a0

10.1126/science.273.5282.1722

10.1023/A:1022366514847

10.1038/10512

10.4049/jimmunol.166.2.1193

10.1016/S0161-5890(01)00041-4

10.1172/JCI0215409

10.1096/fj.02-0209com

10.4049/jimmunol.170.1.503

10.1152/ajpgi.2001.280.5.G974

10.1073/pnas.91.19.8964

Thurston G, 1996, Permeability‐related changes revealed at endothelial cell borders in inflamed venules by lectin binding, Am J Physiol, 271, H2547

10.1073/pnas.95.8.4760

10.1152/ajpgi.00140.2002

10.1016/S0014-2999(99)00382-9

10.1007/BF00918976

10.1038/nri722

10.1016/S1044-5323(02)00128-8

10.1007/s00109-002-0391-x

10.4049/jimmunol.162.1.474

10.4049/jimmunol.164.6.3392

10.4049/jimmunol.166.2.1178

10.1172/JCI119734

10.1002/bjs.4102

10.4049/jimmunol.169.8.4460

10.1128/iai.60.7.2835-2842.1992

10.1136/gut.41.6.832

10.1046/j.1365-2168.2002.02060.x

10.1097/00006676-200210000-00008

10.1136/gut.47.6.838

10.1172/JCI0215849

10.1097/00003246-200208000-00007

10.1097/00003246-200111000-00023

10.1152/ajplung.2000.279.6.L1137

10.5858/2003-127-0331-PEOVEG

10.1164/rccm.2105057

10.1038/nm721

10.1164/rccm.2201012

10.1378/chest.109.3.780

10.1152/ajplung.2001.281.5.L1068

10.1164/ajrccm.162.3.9908099

10.1152/ajpcell.2001.280.4.C719

10.1152/ajplung.1999.276.5.L844

Hu P, 1994, Peroxynitrite inhibition of oxygen consumption and sodium transport in alveolar type II cells, Am J Physiol, 2, L628

Waters CM, 1997, KGF prevents hydrogen peroxide‐induced increases in airway epithelial cell permeability, Am J Physiol, 272, L681

10.1258/0007142991902295

10.1165/ajrcmb.16.2.9032115

10.1067/mhl.2001.118298

10.1172/JCI111386

10.1152/jappl.1988.65.3.1210

10.1164/ajrccm/137.2.420

10.1152/jappl.1993.74.6.2641

Gonzalez PK, 1995, EUK‐8, a synthetic superoxide dismute and catalase mimetic, ameliorates acute lung injury in endotoxemic swine, J Pharmacol Exp Ther, 275, 798

10.4049/jimmunol.166.10.6301

10.1016/S0022-3468(96)90075-5

10.1378/chest.105.1.232

10.1007/BF01708366

10.3109/10715769409056561

10.1002/bjs.1800810913

10.1034/j.1399-3003.1999.13a31.x

10.1007/s001340050813

10.1172/JCI117607

10.1164/ajrccm.163.2.2004187

10.1164/ajrccm.163.1.2005068

10.1007/s001340050876

10.1378/chest.112.1.164

10.1001/jama.1994.03510460064035

10.1007/s001340051128

10.1164/ajrccm.157.5.9707090

10.1097/00003246-199801000-00011

10.1007/s001340101077

10.1016/S0300-2977(01)00120-6

10.1097/00000542-198111000-00010

Bishop MJ, 1983, Hydralazine does not inhibit canine hypoxic pulmonary vasoconstriction, Am Rev Respir Dis, 128, 998

10.1097/00000542-199002000-00005

10.1097/00003246-200210000-00001

10.1056/NEJM199605303342201

10.1164/ajrccm.160.4.9808118

10.1097/00003246-199908000-00013

10.1056/NEJM199703273361303

10.1164/ajrccm/138.1.62

10.1001/jama.280.2.159

10.1016/S0883-9441(99)90001-1

10.1164/ajrccm.155.3.9117028

Abraham E, 2000, Lisofylline versus placebo for ALI and ARDS, Am J Respir Crit Care Med, 161, A379

10.1056/NEJM199102143240701

10.7326/0003-4819-121-1-199407010-00001

10.1097/00003246-199605000-00003

10.1097/00003246-200104000-00015

10.1164/ajrccm.160.3.9809033

10.1055/s-2007-995839

10.1097/01.CCM.0000057842.90746.1E

10.1152/ajplung.00439.2001

10.1172/JCI117169

10.1172/JCI5342

10.1172/JCI6094